

Pharmacy Formulary Updates for June 2018

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in June 2018:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
Norvir tablets	NC
ritonavir tablets	T2
Zavesca	NC
miglustat	T3;PA
Erleada	T2;PA;SP
Rebinyn	MB;PA;SP
Biktarvy	T2
Bevyxxa	T3;QL
Imbruvica tablets	T2;PA
Cimduo	T2
Symfi	T2
Symfi Lo	T2
Zypitamag	NC
celecoxib	T2
Biltricide tablets	NC
praziquantel tablets	T2
Donnatal elixer	Excluded
phenobarbital- hyoscyamine – atropine sulfate- scopolamine Hbr (16.2-0.1037-0.0194-0.0065 mg/5mL) elixer	Excluded

Key:

- MB:** Medical Benefit
- NC:** Not covered
- NTM:** New-to-market
- PA:** Prior Authorization
- QL:** Quantity Limitation
- SP:** Specialty Pharmacy - provided through CVS/specialty
- ST:** Step Therapy